Clinical Trial DelaysThe first launch of TNG462 has been delayed by two years to 2028 to more accurately reflect the company's latest clinical trial plans.
Lack Of Efficacy In Clinical TrialsInvestors were disappointed that the company did not provide efficacy for the 39 evaluable patients at active doses.
Risks Of Negative Clinical ResultsRisks include negative clinical results with the lead asset, TNG908, and delays in advancing pipeline candidates into registrational programs.